Skip to Content


Active Substance: becaplermin
Common Name: becaplermin
ATC Code: D03AX06
Marketing Authorisation Holder: Janssen-Cilag International NV
Active Substance: becaplermin
Status: Withdrawn
Authorisation Date: 1999-03-29
Therapeutic Area: Wound Healing Skin Ulcer
Pharmacotherapeutic Group: Preparations for treatment of wounds and ulcers

Therapeutic Indication

Regranex is indicated, in association with other good wound care measures, to promote granulation and thereby the healing of full-thickness, neuropathic, chronic, diabetic ulcers less than or equal to 5 cm2.

The marketing authorisation for Regranex has been withdrawn at the request of the marketing-authorisation holder.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.